Oxolinic ointment

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT OXOLINIC OINTMENT (OXOLINIUNGUENTUM)

Composition:

Active substance: oxolin;

1 g of ointment contains oxolin (calculated as anhydrous substance) 2.5 mg;

Excipients: mineral oil, white soft paraffin.

Pharmaceutical form. Ointment.

Main physicochemical properties: ointment of white or light yellow color. A pinkish tint may appear during storage.

Pharmacotherapeutic group. Agents acting on the sensory organs. Antimicrobial agents. Antiviral agents. ATC code S01AD.

Pharmacological properties.

Pharmacodynamics.

Oxolin exerts antiviral activity against DNA- and RNA-viruses: adenovirus, influenza virus, herpes simplex virus, and Herpes zoster. The mechanism of the drug's antiviral activity involves chemical interaction with guanine residues of viral nucleic acids, resulting in functionally inactive nucleic acids.

Pharmacokinetics.

When the ointment is applied to the skin and mucous membranes, the drug is rapidly absorbed, partially penetrating into the blood and parenchymatous organs (liver, kidneys, spleen). Oxolin is relatively rapidly excreted from the body with urine and does not accumulate in organs.

Clinical characteristics.

Indications.

Treatment of viral rhinitis, prevention of influenza.

Contraindications.

Hypersensitivity to oxolin and to other components of the drug.

Interaction with other medicinal products and other forms of interaction.

Concomitant intranasal use with adrenomimetic agents may cause excessive drying of the nasal mucosa.

Special precautions for use.

The ointment is not intended for application to the mucous membrane of the eyes. The product must not be applied to damaged skin.

Use during pregnancy or breastfeeding.

Safety data are lacking; therefore, the use of the product during these periods is not recommended.

Ability to affect reaction rate when driving or operating machinery.
Does not affect.

Method of administration and dosage.

Treatment of viral rhinitis: apply the product to the nasal mucosa 2–3 times daily for 3–4 days.

Influenza prophylaxis: during the rise and peak of an epidemic (usually for 25 days) or upon contact with influenza patients, apply the product to the nasal mucosa twice daily (morning and evening).

Children. Data on safety and efficacy in children are lacking.

Overdose.

No cases of overdose have been reported to date.

Symptoms: possible burning sensation on the nasal mucosa and rhinorrhea.

Treatment: discontinue use of the ointment; wash off any residual product with warm water.

Side effects.

At the site of ointment application, transient burning sensation, rhinorrhea, and blue discoloration of the mucous membrane may occur.

Shelf life. 3 years.

Do not use the product after the expiry date stated on the package.

Storage conditions.

Store at a temperature not exceeding 10 °C, in a place inaccessible to children.

Packaging.

10 g in a tube in a carton, 10 g in containers.

Availability. Over-the-counter.

Manufacturer.

LLC "DKP "Pharmaceutical Factory".

Manufacturer's address and place of business.

Ukraine, 12430, Zhytomyr region, Zhytomyr district, village Stanishivka, Korolyova St., b. 4.